Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Summit's market cap today is close to $15 billion and shares trade for about $19 each, up 989% over the past year. For anyone ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

The latest update is out from Summit Therapeutics ( (SMMT) ).

“Completing enrollment in the first global study for ivonescimab is a credit to the growing belief in the potential for ivonescimab to make a significant difference in the lives of patients ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy called ivonescimab. The stock market has been pushing up Summit's stock ...

The company has not yet had any sales of its products. Its first potential drug, ivonescimab, is in phase 3 clinical testing. Ivonescimab works similarly to Merck's pembrolizumab by making cancer ...